Logo image of BBIO

BRIDGEBIO PHARMA INC (BBIO) Stock Fundamental Analysis

NASDAQ:BBIO - Nasdaq - US10806X1028 - Common Stock - Currency: USD

36.85  +0.05 (+0.12%)

After market: 36.85 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to BBIO. BBIO was compared to 571 industry peers in the Biotechnology industry. BBIO may be in some trouble as it scores bad on both profitability and health. BBIO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BBIO has reported negative net income.
In the past year BBIO has reported a negative cash flow from operations.
In the past 5 years BBIO always reported negative net income.
In the past 5 years BBIO always reported negative operating cash flow.
BBIO Yearly Net Income VS EBIT VS OCF VS FCFBBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -200M -400M -600M

1.2 Ratios

BBIO's Return On Assets of -66.00% is on the low side compared to the rest of the industry. BBIO is outperformed by 63.06% of its industry peers.
Industry RankSector Rank
ROA -66%
ROE N/A
ROIC N/A
ROA(3y)-83.5%
ROA(5y)-71.11%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BBIO Yearly ROA, ROE, ROICBBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600

1.3 Margins

BBIO's Gross Margin of 98.90% is amongst the best of the industry. BBIO outperforms 98.40% of its industry peers.
BBIO's Gross Margin has declined in the last couple of years.
BBIO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 98.9%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.67%
GM growth 5YN/A
BBIO Yearly Profit, Operating, Gross MarginsBBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K

More info and screens

2

2. Health

2.1 Basic Checks

BBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
BBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BBIO Yearly Shares OutstandingBBIO Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M
BBIO Yearly Total Debt VS Total AssetsBBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B

2.2 Solvency

Based on the Altman-Z score of -5.52, we must say that BBIO is in the distress zone and has some risk of bankruptcy.
BBIO has a Altman-Z score of -5.52. This is in the lower half of the industry: BBIO underperforms 64.48% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.52
ROIC/WACCN/A
WACC8.91%
BBIO Yearly LT Debt VS Equity VS FCFBBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 1B -1B

2.3 Liquidity

BBIO has a Current Ratio of 3.19. This indicates that BBIO is financially healthy and has no problem in meeting its short term obligations.
BBIO's Current ratio of 3.19 is on the low side compared to the rest of the industry. BBIO is outperformed by 62.34% of its industry peers.
BBIO has a Quick Ratio of 3.19. This indicates that BBIO is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.19, BBIO is not doing good in the industry: 60.57% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 3.19
Quick Ratio 3.19
BBIO Yearly Current Assets VS Current LiabilitesBBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

More info and screens

4

3. Growth

3.1 Past

BBIO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 23.86%, which is quite impressive.
EPS 1Y (TTM)23.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-36.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%236.96%

3.2 Future

Based on estimates for the next years, BBIO will show a very strong growth in Earnings Per Share. The EPS will grow by 25.36% on average per year.
BBIO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 61.14% yearly.
EPS Next Y-24.44%
EPS Next 2Y3.3%
EPS Next 3Y10.35%
EPS Next 5Y25.36%
Revenue Next Year-16%
Revenue Next 2Y42.48%
Revenue Next 3Y57.68%
Revenue Next 5Y61.14%

3.3 Evolution

BBIO Yearly Revenue VS EstimatesBBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
BBIO Yearly EPS VS EstimatesBBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6 8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BBIO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BBIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BBIO Price Earnings VS Forward Price EarningsBBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BBIO Per share dataBBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.3%
EPS Next 3Y10.35%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BBIO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BRIDGEBIO PHARMA INC

NASDAQ:BBIO (2/21/2025, 8:02:48 PM)

After market: 36.85 0 (0%)

36.85

+0.05 (+0.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-20 2025-02-20/bmo
Earnings (Next)04-30 2025-04-30/bmo
Inst Owners78.13%
Inst Owner Change2.64%
Ins Owners2.41%
Ins Owner Change-142.97%
Market Cap6.96B
Analysts81.82
Price Target52.57 (42.66%)
Short Float %12.17%
Short Ratio8.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)26.93%
Min EPS beat(2)-10.2%
Max EPS beat(2)64.07%
EPS beat(4)2
Avg EPS beat(4)31.21%
Min EPS beat(4)-10.2%
Max EPS beat(4)74.34%
EPS beat(8)2
Avg EPS beat(8)8.17%
EPS beat(12)4
Avg EPS beat(12)11.96%
EPS beat(16)5
Avg EPS beat(16)5.39%
Revenue beat(2)0
Avg Revenue beat(2)-34.63%
Min Revenue beat(2)-40.46%
Max Revenue beat(2)-28.8%
Revenue beat(4)1
Avg Revenue beat(4)308.28%
Min Revenue beat(4)-72.53%
Max Revenue beat(4)1374.92%
Revenue beat(8)1
Avg Revenue beat(8)134.97%
Revenue beat(12)2
Avg Revenue beat(12)102.32%
Revenue beat(16)3
Avg Revenue beat(16)62.2%
PT rev (1m)2.59%
PT rev (3m)5.06%
EPS NQ rev (1m)0.94%
EPS NQ rev (3m)-536.58%
EPS NY rev (1m)1.95%
EPS NY rev (3m)-33.77%
Revenue NQ rev (1m)11.01%
Revenue NQ rev (3m)-98.48%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)-36.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 31.98
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3
EYN/A
EPS(NY)-3.73
Fwd EYN/A
FCF(TTM)-2.41
FCFYN/A
OCF(TTM)-2.38
OCFYN/A
SpS1.15
BVpS-6.51
TBVpS-6.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -66%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 98.9%
FCFM N/A
ROA(3y)-83.5%
ROA(5y)-71.11%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.67%
GM growth 5YN/A
F-Score4
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 97.06%
Cap/Sales 2.8%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.19
Quick Ratio 3.19
Altman-Z -5.52
F-Score4
WACC8.91%
ROIC/WACCN/A
Cap/Depr(3y)113.45%
Cap/Depr(5y)N/A
Cap/Sales(3y)13.73%
Cap/Sales(5y)29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-36.46%
EPS Next Y-24.44%
EPS Next 2Y3.3%
EPS Next 3Y10.35%
EPS Next 5Y25.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%236.96%
Revenue Next Year-16%
Revenue Next 2Y42.48%
Revenue Next 3Y57.68%
Revenue Next 5Y61.14%
EBIT growth 1Y2.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.59%
EBIT Next 3Y7.57%
EBIT Next 5Y14.83%
FCF growth 1Y2.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.16%
OCF growth 3YN/A
OCF growth 5YN/A